Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Complera in Healthy Japanese Men
NCT02530060Phase 4Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2015
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of emtricitabine + rilpivirine + tenofovir disoproxil fumarate in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Janssen Pharmaceutical. Started Aug 2015; status: completed.
02
Drugs
emtricitabine + rilpivirine + tenofovir disoproxil fumarate
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02530060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02530060.